Certain types of anti-diabetic medications may lower the risk of Parkinson’s disease in people with type 2 diabetes, a population-based study suggests. In particular, the risk of Parkinson’s was found to be 36–60% lower in diabetic patients who were being treated with GLP-1 agonists or DPP4…
The interplay between different genetic and environmental factors, from a family history of disease to smoking habits, contributes to Parkinson’s risk and can help in designing tests that better allow for its early detection, a study suggests. The study, “Parkinson’s disease determinants, prediction and gene–environment interactions in the UK…
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) is partnering with Acadia Pharmaceuticals to provide patients and caregivers with free educational materials focused on cognitive changes and other non-motor symptoms of the disease. Of the roughly six million people globally who live with Parkinson’s, some 40%…
An innovative computational approach for identifying new alpha-synuclein tracer molecules could be used to track the progression of Parkinson’s disease, according to a recent study. The study, “Identification of a nanomolar affinity α-synuclein fibril imaging probe by ultra-high throughput in silico…
A new compound called CLR01, which works like a “molecular tweezer” to clear toxic protein clumps that accumulate in brain cells, could become a promising therapy to slow Parkinson’s disease progression, a study suggests. The study, “CLR01 protects dopaminergic neurons in vitro and in mouse models of Parkinson’s…
Previous falls, hallucinations, and cognitive problems are among the factors that predict a risk of recurrent falls in elderly people with parkinsonian gait, a study suggests. The study, “Parkinsonian gait in elderly people: Significance of the threshold value of two and more falls per year,” was published in the…
Targeting certain regions of the alpha-synuclein protein could be a viable therapeutic strategy for Parkinson’s disease, a study suggests. The study, “Two C-terminal sequence variations determine differential neurotoxicity between human and mouse α-synuclein,” was published in the journal Molecular Neurodegeneration. Parkinson’s disease is characterized by…
Through a partnership, the Parkinson’s Foundation and Amazon’s Alexa cloud-based voice service are helping to make Parkinson’s (PD) education and resources available to more people. Alexa-enabled devices now cite Parkinson’s Foundation sources, in English or Spanish, when answering questions about the disease. Alexa is available on Amazon Echo…
Parkinson’s disease patients have an increased risk of dying from COVID-19, a recent study suggests. This heightened risk may be due to the development of pneumonia caused by the virus, a respiratory condition that is a leading cause of death in Parkinson’s patients. The study, “COVID-19 case fatality and Parkinson’s…
STADA Arzneimittel has announced the acquisition of Sweden-based Lobsor Pharmaceuticals, gaining the rights to its triple-combination therapy of levodopa, carbidopa, and entacapone, delivered via modern pump technology, as a treatment for patients with late-stage Parkinson’s disease. The triple-combo treatment has already been approved in most…
Get regular updates to your inbox.
